Harmony Biosciences Holdings Inc
Avatud
SektorTervishoid
33.96 0.47
Ülevaade
Aktsiahinna muutus
24h
Min
33.32
Max
34.54
Sissetulek | 10M 32M |
|---|---|
Müük | -28M 215M |
P/E Sektori keskmine | 12.984 49.052 |
Aktsiakasum | 0.786 |
Kasumimarginaal | 15.084 |
Töötajad | 293 |
EBITDA | -2.8M 49M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +44.82% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -22M 1.9B |
|---|---|
Eelmine avamishind | 33.49 |
Eelmine sulgemishind | 33.96 |
Uudiste sentiment
By Acuity
100%
0%
325 / 342 Pingereas Healthcare
Harmony Biosciences Holdings Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
